Anavex Life Sciences (AVXL) Stock Forecast, Price Target & Predictions
AVXL Stock Forecast
Anavex Life Sciences stock forecast is as follows: an average price target of $11.00 (represents a 21.95% upside from AVXL’s last price of $9.02) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
AVXL Price Target
The average price target for Anavex Life Sciences (AVXL) is $11.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $11.00. This represents a potential 21.95% upside from AVXL's last price of $9.02.
AVXL Analyst Ratings
According to 7 Wall Street analysts, Anavex Life Sciences's rating consensus is 'Buy'. The analyst rating breakdown for AVXL stock is 0 'Strong Buy' (0.00%), 5 'Buy' (71.43%), 2 'Hold' (28.57%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Anavex Life Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 06, 2022 | Cantor Fitzgerald | - | - | 28.85% | 21.95% |
The latest Anavex Life Sciences stock forecast, released on Dec 06, 2022 by Cantor Fitzgerald company, set a price target of $11.00, which represents a 28.85% increase from the stock price at the time of the forecast ($8.54), and a 21.95% increase from AVXL last price ($9.02).
Anavex Life Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $9.02 | $9.02 | $9.02 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Anavex Life Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Anavex Life Sciences's last price of $9.02. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 18, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 22, 2024 | EF Hutton | Buy | Initialise | |
| Jan 03, 2023 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jan 03, 2023 | Keefe, Bruyette & Woods | Outperform | Outperform | Hold |
| Jan 03, 2023 | Needham | Buy | Buy | Hold |
| Jan 03, 2023 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 06, 2022 | Cantor Fitzgerald | Neutral | Downgrade |
Anavex Life Sciences's last stock rating was published by H.C. Wainwright on Oct 18, 2024. The company gave AVXL a "Buy" rating, the same as its previous rate.
Anavex Life Sciences Financial Forecast
Anavex Life Sciences Revenue Forecast
| Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $111.56M | $71.73M | $45.53M | $45.92M | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $111.56M | $71.73M | $45.53M | $45.92M | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | $111.56M | $71.73M | $45.53M | $45.92M | - | - |
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Anavex Life Sciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. AVXL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Anavex Life Sciences EBITDA Forecast
| Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
undefined analysts predict AVXL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Anavex Life Sciences's previous annual EBITDA (undefined) of $NaN.
Anavex Life Sciences Net Income Forecast
| Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $275.50M | $263.05M | $260.95M | $257.60M | $191.77M | $183.30M | $182.04M | $179.50M | $123.58M | $126.13M | $128.27M | $129.11M | $-14.15M | $-15.62M | $-13.94M | $-13.81M | $-13.95M | $-13.53M |
| High Forecast | $275.50M | $263.05M | $260.95M | $257.60M | $191.77M | $183.30M | $182.04M | $179.50M | $123.58M | $126.13M | $128.27M | $129.11M | $-14.15M | $-15.62M | $-13.94M | $-13.81M | $-13.95M | $-13.53M |
| Low Forecast | $275.50M | $263.05M | $260.95M | $257.60M | $191.77M | $183.30M | $182.04M | $179.50M | $123.58M | $126.13M | $128.27M | $129.11M | $-14.15M | $-15.62M | $-13.94M | $-13.81M | $-13.95M | $-13.53M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Anavex Life Sciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AVXL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Anavex Life Sciences SG&A Forecast
| Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Anavex Life Sciences's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to AVXL last annual SG&A of $NaN (undefined).
Anavex Life Sciences EPS Forecast
| Sep 28 | Jun 28 | Mar 28 | Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | 1 | 1 | - | - |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $3.26 | $3.11 | $3.09 | $3.05 | $2.27 | $2.17 | $2.15 | $2.12 | $1.46 | $1.49 | $1.52 | $1.53 | $-0.17 | $-0.18 | $-0.16 | $-0.16 | $-0.16 | $-0.16 |
| High Forecast | $3.26 | $3.11 | $3.09 | $3.05 | $2.27 | $2.17 | $2.15 | $2.12 | $1.46 | $1.49 | $1.52 | $1.53 | $-0.17 | $-0.18 | $-0.16 | $-0.16 | $-0.16 | $-0.16 |
| Low Forecast | $3.26 | $3.11 | $3.09 | $3.05 | $2.27 | $2.17 | $2.15 | $2.12 | $1.46 | $1.49 | $1.52 | $1.53 | $-0.17 | $-0.18 | $-0.16 | $-0.16 | $-0.16 | $-0.16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Anavex Life Sciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AVXL previous annual EPS of $NaN (undefined).
Anavex Life Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BTAI | BioXcel Therapeutics | - | - | 2005.26% | Buy |
| NVAX | Novavax | - | - | 531.84% | Buy |
| KOD | Kodiak Sciences | - | - | 435.59% | Buy |
| INMB | INmune Bio | - | - | 362.18% | Buy |
| ANVS | Annovis Bio | - | - | 278.06% | Buy |
| IOVA | Iovance Biotherapeutics | - | - | 154.85% | Buy |
| VKTX | Viking Therapeutics | - | - | 98.33% | Buy |
| AXSM | Axsome Therapeutics | - | - | 24.68% | Buy |
| AVXL | Anavex Life Sciences | - | - | 21.95% | Buy |
| MDGL | Madrigal Pharmaceuticals | - | - | -4.10% | Buy |
| EXEL | Exelixis | - | - | -12.43% | Buy |
| TGTX | TG Therapeutics | - | - | -20.12% | Buy |